HCPCS Q5107: Bevacizumab-awwb (Mvasi) Injection, 10 mg

HCPCS Level II code Q5107 designates a 10 mg unit of bevacizumab-awwb (Mvasi), a biosimilar to bevacizumab used primarily in oncology and related indications. This billing code identifies the drug product for billing and inventory purposes and matters nationally because bevacizumab biosimilars affect drug procurement, oncology treatment costs, and payer coverage policies across outpatient infusion settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the code’s clinical context and typical sites of service, as well as what to expect from payer coverage patterns and benchmarks where available. The publication summarizes billing considerations for unit-based biosimilar drug coding, highlights common modifiers used in practice (list provided separately), and outlines the operational implications for hospital outpatient departments and infusion centers.

This overview also describes the practical use of Q5107 on service lines, how it interacts with drug administration workflows, and the types of content included in the full publication (benchmarks, policy updates, and clinical context). Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Billing Code Overview

HCPCS Level II code Q5107 represents injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg. This code denotes a 10 mg unit of the biosimilar bevacizumab-awwb (Mvasi) product used for systemic administration.

Service type: Parenteral administration of a biosimilar monoclonal antibody for oncologic and other indicated uses.
Typical site of service: Hospital outpatient departments, physician offices/infusion centers, and ambulatory infusion centers where intravenous or other parenteral biologic therapies are administered.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical Context

A 62-year-old female with metastatic colorectal adenocarcinoma presents to an outpatient oncology infusion clinic for systemic therapy. Her oncologist prescribes bevacizumab-awwb (Q5107) as part of a chemotherapy regimen to inhibit tumor angiogenesis. The clinical workflow begins with verification of the current chemotherapy order, allergy and vital sign assessment, review of recent labs (including basic metabolic panel and CBC), and confirmation of informed consent. The drug is prepared by the clinic pharmacy in a sterile environment and delivered to the infusion suite. A registered nurse performs vascular access, administers the infusion per institution protocol (IV infusion over the recommended timeframe), monitors for infusion reactions and hypertension during and after administration, documents lot number and units billed using the Q5107 HCPCS (per 10 mg unit), and provides post-infusion instructions. Typical sites of service include outpatient oncology infusion centers, hospital outpatient departments, and ambulatory infusion clinics.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug wastage (discarded portion)	Use to report discarded portion of single-dose vial when billing only the amount administered and documenting wastage.

Taxonomy Code	Specialty	Notes
207RG0100X	Hematology/Oncology	Medical oncologists who order and manage systemic biologic therapies.
2084P0800X	Oncology Nursing	Registered nurses specializing in oncology infusion administration and monitoring.
363L00000X	Infusion Therapy	Infusion clinic providers and pharmacists overseeing biologic preparation and administration.
207L00000X	Internal Medicine	Hospitalists or internists involved in inpatient administration and management of systemic therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Colorectal cancers commonly use bevacizumab in metastatic settings to inhibit angiogenesis.
`C20`	Malignant neoplasm of rectum	Rectal adenocarcinoma with metastatic disease may be treated with bevacizumab-containing regimens.
`C34.90`	Malignant neoplasm of unspecified part of bronchus or lung	Non–small cell lung cancer regimens sometimes include bevacizumab for eligible patients.
`C50.919`	Malignant neoplasm of unspecified site of right female breast	Metastatic breast cancer historically may be considered for anti-angiogenic therapy in select cases.
`C71.9`	Malignant neoplasm of brain, unspecified	Bevacizumab is used in recurrent glioblastoma and other CNS malignancies in certain indications.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, infusion technique; intravenous infusion, up to 1 hour, single or initial substance/drug	Commonly used to report the IV infusion administration time when bevacizumab-awwb is administered as the initial drug in a chemotherapy infusion session.
`96415`	Chemotherapy administration, each additional hour (list separately in addition to code for primary service)	Used when infusion duration for bevacizumab-awwb extends beyond the initial hour and additional time is billed.
`96417`	Chemotherapy administration, each additional sequential infusion, up to 1 hour	Used when multiple sequential infusions are performed in the same visit and bevacizumab-awwb is one of the infusions.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	May be used in non-oncology infusion settings when a biologic infusion is billed outside of chemotherapy-specific administration codes.
`36415`	Collection of venous blood by venipuncture	Performed prior to infusion for labs such as CBC and chemistries used to determine eligibility for bevacizumab-awwb therapy.

OpenPayer

Summary & Overview